NON-ALCOHOLIC STEATOHEPATITIS

This early-stage trial tested the safety and tolerability of a new drug called J2H-1702, designed for non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. It involved 100 healthy men aged 19 to 45. The study was placebo-controlled and dose-escalating to find the s…

This study tested an experimental drug called MGL-3196 in 125 adults with non-alcoholic steatohepatitis (NASH), a serious liver condition caused by fat buildup. The main goal was to see if the drug could reduce liver fat after 12 weeks compared to a placebo. The trial was complet…

This study tested an experimental drug called ARO-HSD in 50 people, including healthy volunteers and patients with NASH (a serious fatty liver disease). The main goal was to check safety and how the drug moves through the body. Researchers gave single or multiple doses to see if …

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and whether it can reduce liver fat and scarring over 12 weeks compared to a placebo. Participants had to ha…

This study tested whether combining a new liver medicine (NNC0194-0499) with semaglutide (a diabetes and weight-loss drug) can reduce liver scarring in people with NASH, a serious fatty liver disease. About 698 adults received weekly injections of either the drug combo, a differe…

This study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also measuring if the drug could improve fibrosis. Results help guide future resea…

This early-stage study tested the safety and how the body processes a new drug called ACT500 in 72 healthy Chinese adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was not to treat any disease, but to gather important safety …

This study examined medical records of 263 adults with biopsy-confirmed NASH to see how factors like age, other health problems, and medications relate to the severity of liver scarring. Researchers focused on metabolic syndrome components as potential risk factors. No treatments…

This study checked if a special MRI scan called LiverMultiScan gives the same results when repeated on the same machine or on different machines. 61 adults with various liver diseases were scanned multiple times. The goal was to see if the scan reliably measures liver fat, iron, …

This study tested a new ultrasound feature that measures liver fat by comparing it to the standard MRI method. 60 adults with or at risk for fatty liver disease had both scans. The goal was to see if the simpler, cheaper ultrasound could give reliable results, potentially making …

This study tested a new ultrasound feature that aims to measure liver fat in children, comparing it to the standard MRI method. Thirty children aged 5 to 21 with or at risk for fatty liver disease took part. The goal was to see if the quicker, cheaper ultrasound could give result…

This early-phase study tested a single dose of the experimental drug J2H-1702 in 16 healthy women aged 19 to 45. The main goal was to check if the drug is safe and how the body processes it. This is a first step toward possibly treating non-alcoholic steatohepatitis (NASH), a ser…

This study looked at how the body processes efinopegdutide, a potential drug for fatty liver disease, in people with moderate to severe liver damage compared to healthy people. A total of 22 adults received a single dose, and researchers measured drug levels and safety. The goal …